Novo Nordisk Launches Bidding War With Pfizer for Metsera Acquisition
Novo Nordisk’s unsolicited bid for Metsera came a month after Pfizer’s deal with the firm. Pfizer said it will ‘pursue all legal avenues’ to protect its rights.
The logo of Danish pharmaceutical company Novo Nordisk at their headquarters in Bagsvaerd, Denmark, on Feb. 1, 2017. Liselotte Sabroe/Scanpix Denmark/AFP via Getty Images
Novo Nordisk, the Denmark-based Ozempic creator, has launched a bidding war with Pfizer Inc. to acquire New York-based Metsera Inc.
Founded in 2022, Metsera is a clinical-stage biopharmaceutical firm specializing in treatments for obesity and metabolic diseases.
Mary Prenon
Freelance Reporter
Mary T. Prenon covers real estate and business. She has been a writer and reporter for over 25 years with various print and broadcast media in New York.
